Oral vs Topical Minoxidil: Regrowth Results Compared
How do regrowth results compare between low-dose oral minoxidil and topical minoxidil?
Most people ask which one grows more hair, and the trials keep answering the same unsatisfying way: at comparable doses, they're close enough that neither has claimed the win. What actually separates them is what you'll still be doing in two years, and what you're willing to accept in exchange. Route matters less than dose, duration and whether you keep using it.
| What you're weighing | Low-dose oral | 5 percent topical |
|---|---|---|
| Density gain at 6 months | Comparable, often numerically ahead | Comparable, no proven deficit |
| Daily routine | One tablet, seconds | Measure, part, apply, dry, once or twice daily |
| Side effect profile | Systemic: body hair, swelling, palpitations | Local: itching, flaking, irritation |
| Regulatory standing | Off-label for hair loss | Approved for pattern hair loss |
Randomized head-to-head trials of 1 mg daily oral minoxidil against 5 percent topical in women, and 5 mg daily against 5 percent twice daily in men, both found comparable hair density gains at 24 weeks with no trial demonstrating overall superiority for the tablet.
What do head-to-head trials show about hair count and density gains for each route?
You can count the direct comparisons on one hand, and both of the ones people quote ran for 24 weeks. Read side by side they aren't contradictory, they're a dose story. The gains are real and measurable, but they're smaller than the picture in your head.
- Women's trial, 1 mg oral against 5 percent once daily: Both arms improved; the gap wasn't statistically significant.
- Men's trial, 5 mg oral against 5 percent twice daily: Both improved; oral ahead only on vertex photographs.
- Absolute gain: Roughly 10 to 15 terminal hairs per square centimetre in the oral arm.
- What density measures: One marked patch of scalp, terminal hairs only, not the whole head.
Neither route is the better pick on trial data alone, since both randomized head-to-head studies showed improvement in both arms, with oral gains of roughly 10 to 15 terminal hairs per square centimetre and no statistically significant advantage over topical.
How quickly does visible regrowth appear on each route, and when do gains plateau?
The first thing you'll notice isn't growth, it's shedding, and that's exactly where most people quit. Both routes run on the same clock, because they're both working on your hair cycle rather than on anything the drug does faster in a tablet.
- Weeks 2 to 4: Resting follicles restart and release the old hairs still sitting in them, so shedding climbs.
- The next 3 to 6 weeks: That shed settles, and it reads as the drug engaging rather than failing.
- Months 3 to 4: New hairs are finally long enough and pigmented enough to register in a mirror.
- Month 6: The earliest point you can judge the result fairly.
- Month 12: The response hits its ceiling, and treatment shifts from gaining ground to holding it.
Both routes take three to four months before regrowth is visible, six months before a fair judgement can be made and roughly twelve months to reach their ceiling, and both surrender the gains over the months after stopping.
Which scalp regions and pattern-loss stages respond better to a systemic dose than to a surface one?
Region matters more than you'd expect, and it pushes both routes in the same direction. Your crown still holds follicles that have shrunk but haven't given up; a hairline that receded years ago mostly doesn't. Where a tablet genuinely wins isn't strength, it's covering the spots your hand keeps missing.
The vertex and mid-scalp respond best on both routes while a receded temporal hairline responds least, and the systemic route's real advantage is even coverage rather than greater potency, since a tablet reaches every follicle at the same concentration.
Why does scalp sulfotransferase activity explain why one route works for someone and the other does not?
Minoxidil does nothing to a follicle as it comes out of the bottle. It's a prodrug, and your scalp has to switch it on with an enzyme you may or may not have much of. That one variable is the cleanest explanation for why the same product transforms your friend's crown and does nothing at all to yours.
- The enzyme: SULT1A1 in the outer root sheath converts minoxidil into active minoxidil sulfate.
- How common low activity is: Reported in roughly 60 percent of people, predicting poor topical response.
- Why a tablet can rescue it: Sulfation can happen in the liver, not only in the follicle.
- What it doesn't explain: Penetration, miniaturization stage, androgen sensitivity and plain consistency all still count.
Minoxidil is a prodrug activated by the sulfotransferase enzyme SULT1A1, and low scalp activity, reported in roughly 60 percent of the population, predicts poor topical response while an oral dose allows sulfation to occur in the liver as well as in the follicle.
How does the dose chosen change the size of any regrowth difference between the two routes?
Dose quietly decides most of these comparisons, and it's the one thing almost nobody holds constant. Check what was actually paired against what before you accept anyone's conclusion, because 1 mg against 5 percent twice daily and 5 mg against 5 percent once daily are different experiments with predictably different winners.
| Dosing question | Oral route | Topical route |
|---|---|---|
| Usual range | 0.25 mg to 5 mg daily | 2 or 5 percent, 1 mL or half a capful |
| Step up in strength | Every extra milligram adds density at 6 months | 2 to 5 percent adds about 45 percent more regrowth |
| What the step costs | Each extra milligram raises unwanted body hair risk by about 18 percent | Twice daily beats once daily by a small margin |
| Systemic exposure | The full dose circulates | Around 1 to 2 percent absorbed through intact scalp |
Oral minoxidil for hair loss is used across a 0.25 mg to 5 mg daily range, where every additional milligram adds hair density at six months while raising the risk of unwanted body hair by roughly 18 percent, whereas topical strength moves only from 2 percent to 5 percent for about 45 percent more regrowth.
How much of the real-world difference in results comes down to sticking with the routine?
Efficacy is what a drug does in a trial. Effectiveness is what it does for you, alone in your bathroom at eleven at night, on day four hundred. The gap between those two numbers is wide enough to swallow every difference the trials measured.
In a series of 400 people with androgenetic alopecia, 86 percent had stopped using topical minoxidil and only about 12 percent were still using it beyond a year, so real-world persistence rather than potency is the strongest practical argument for the oral route.
Do the side effect profiles cancel out any regrowth advantage in practice?
For plenty of people, yes, and you deserve that answer straight even where the tablet grows more hair. The two profiles barely overlap, so you aren't choosing a bigger or smaller risk, you're choosing a different kind of one. Don't let anyone start you on a tablet without a blood pressure reading and a cardiac and kidney history first.
| Effect | Low-dose oral | Topical |
|---|---|---|
| Unwanted facial and body hair | About 15 percent in the largest series, rising sharply with dose | Around 1 in 8, often where liquid has run |
| Local scalp problems | None | Itching, flaking, irritation, occasional contact dermatitis |
| Fluid retention or ankle swelling | Roughly 1 to 10 percent | Effectively none |
| Palpitations | About 1 to 4 percent | Effectively none |
| Lightheadedness on standing | About 1 to 2 percent | Effectively none |
Low-dose oral minoxidil causes unwanted body hair in about 15 percent of users in the largest series, fluid retention in roughly 1 to 10 percent and palpitations in about 1 to 4 percent, while the serious cardiac events in the drug's history came from antihypertensive doses of 10 to 40 mg daily rather than hair-loss doses.
What happens to regrowth when someone switches routes or uses both together?
Switching is the more common move and the better supported one. If you're about to write off a topical product, make sure you actually gave it the run it needs, because most apparent non-response is under-use rather than biology. Running both at once is a different proposition, and the burden adds up more reliably than the benefit does.
Six to eight months of genuine daily use is the point at which topical minoxidil can fairly be called a failure, and a switch should overlap or step straight across rather than pause, because a break of several weeks allows post-withdrawal loss to begin.
How strong is the evidence base behind these comparisons, and where is it thin?
The confidence you'll find online about this comparison isn't matched by what's actually been measured. Topical minoxidil rests on decades of large placebo-controlled trials, while the oral route rests on a much younger literature of case series, open-label work and a handful of small randomized studies. That gap is worth knowing before you treat any head-to-head claim as settled.
- Direct comparisons: Low single figures, and the most cited ones ran only 24 weeks.
- Oral study sizes: Usually dozens of participants, often from the same few centres.
- Who's missing: Older adults and people with cardiac or kidney disease, excluded by design.
- Why papers disagree: Endpoints vary between marked-area density, total hair count and blinded photographs.
Direct head-to-head comparisons of oral and topical minoxidil number in the low single figures and the most cited ones ran only 24 weeks against a response that peaks at around twelve months, so the defensible statement is that the two routes produce comparable regrowth at comparable doses.
